Blend Therapeutics, Inc. is discovering and developing integrative combination medicines with the unprecedented ability to precisely control each agent's therapeutic action in concert. Using the company's proprietary Maestro platform, Blend designs and integrates drugs to target distinct disease pathways with optimal efficacy and safety. Blend was founded by three leaders in the fields of chemistry and nanomedicine from the Massachusetts Institute of Technology (MIT) and Harvard Medical School: Dr. Robert Langer and Dr. Stephen Lippard of MIT, and Dr. Omid Farokhzad of Harvard Medical School.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/09/12 | undisclosed |
Flagship Ventures NanoDimension | undisclosed | |
| 12/19/12 | $16,000,000 | Series B |
Flagship Ventures NanoDimension | undisclosed |
| 01/07/15 | $21,000,000 | Series B Extension |
Flagship Ventures NanoDimension | undisclosed |
| 01/27/16 | $38,000,000 | Series C |
Eminent Venture Capital Flagship Ventures NanoDimension Novo A/S | undisclosed |
